Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H23Cl2N3O3S |
| Molecular Weight | 468.397 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCS(=O)(=O)NC(=O)C1=CC2=C(C=C1)N=C(C)N2CC3=CC=C(Cl)C=C3Cl
InChI
InChIKey=UYGZODVVDUIDDQ-UHFFFAOYSA-N
InChI=1S/C21H23Cl2N3O3S/c1-3-4-5-10-30(28,29)25-21(27)15-7-9-19-20(11-15)26(14(2)24-19)13-16-6-8-17(22)12-18(16)23/h6-9,11-12H,3-5,10,13H2,1-2H3,(H,25,27)
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties. | 2006-08 |
|
| Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor gamma. | 2006-03 |
|
| FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. | 2005-12 |
|
| Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat. | 2005-09-05 |
|
| FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs. | 2005-09 |
Patents
Sample Use Guides
FK-614, rosiglitazone, and pioglitazone competed for specific binding of [3H]rosiglitazone to peroxisome proliferator-activated receptor gamma (PPARgamma) with Ki values of 11 nM, 47 nM, and 1.3 microM, respectively. K614 induced interaction of PPARgamma with nuclear receptor coactivator CBP but of lower magnitude than rosiglitazone and pioglitazone. The estimated Kd values of FK614-, rosiglitazone-, and pioglitazone-PPARgamma complex to CBP peptide were 1.8, 0.64, and 0.72 microM, respectively, indicating FK-614/PPARgamma complex exhibits a lower affinity for CBP peptide compared to other agonist-PPARgamma complexes.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
V5Q32BZX79
Created by
admin on Mon Mar 31 18:04:06 GMT 2025 , Edited by admin on Mon Mar 31 18:04:06 GMT 2025
|
PRIMARY | |||
|
9869229
Created by
admin on Mon Mar 31 18:04:06 GMT 2025 , Edited by admin on Mon Mar 31 18:04:06 GMT 2025
|
PRIMARY | |||
|
DB12557
Created by
admin on Mon Mar 31 18:04:06 GMT 2025 , Edited by admin on Mon Mar 31 18:04:06 GMT 2025
|
PRIMARY | |||
|
DTXSID60940978
Created by
admin on Mon Mar 31 18:04:06 GMT 2025 , Edited by admin on Mon Mar 31 18:04:06 GMT 2025
|
PRIMARY | |||
|
193012-35-0
Created by
admin on Mon Mar 31 18:04:06 GMT 2025 , Edited by admin on Mon Mar 31 18:04:06 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
